Saturday, October 31, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

How The Great-West Lifeco (TSX:GWO) Story Is Shifting As Capital Strength Meets Sector Pressures

View original at finance.yahoo.com
How The Great-West Lifeco (TSX:GWO) Story Is Shifting As Capital Strength Meets Sector Pressures Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CIBC set price target of CA$73 for Great-West Lifeco with Outperform rating, signaling confidence in the company's ability to execute on its plan

    60% confidence

  • BMO Capital trimmed price target to CA$66 and maintains Market Perform rating, highlighting a more cautious stance

    60% confidence

  • RBC Capital moved price target higher to CA$64 with Sector Perform rating, suggesting shares are reasonably placed within the life insurance peer group

    60% confidence

  • Barclays flags headwinds such as spread compression and technology spending for life insurers, which can pressure profitability

    60% confidence

  • Scotiabank set price target of CA$71 for Great-West Lifeco with Outperform rating, signaling confidence in the company's ability to execute on its plan

    60% confidence

  • Barclays moved price target to CA$70 with Equal Weight rating, pointing to capital strength, cash flow and industry consolidation as supports for life insurers heading into 2026

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com